Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$1,160.00 USD

1,160.00
2,390,318

+3.27 (0.28%)

Updated Sep 1, 2026 04:04 PM ET

After-Market: $1,159.61 -0.39 (-0.03%) 6:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 248)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ekta Bagri headshot

Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?

by Ekta Bagri

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.

Yashwardhan Jain headshot

Top-Ranked ETFs to Power Your Portfolio Higher

by Yashwardhan Jain

With market tailwinds building and optimism returning, these top-ranked ETFs can help investors capture momentum safely.

Zacks Equity Research

Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi

by Zacks Equity Research

Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.

Kinjel Shah headshot

LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock

by Kinjel Shah

Lilly trades above key SMAs as strong GLP-1 demand, new drugs and pipeline momentum drive shares.

Kinjel Shah headshot

3 Large Drug Stocks to Watch as the Industry Shows Some Recovery

by Kinjel Shah

In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.

Sundeep Ganoria headshot

How Strong Is AbbVie's Immunology Franchise After Humira's LOE?

by Sundeep Ganoria

ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.

Ahan Chakraborty headshot

Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?

by Ahan Chakraborty

Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.

Zacks Equity Research

LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website

by Zacks Equity Research

Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.

Sanghamitra Saha headshot

Best-Performing ETFs of November

by Sanghamitra Saha

November muted for markets, but ETFs like SPYM, BWET, WNTR, LITP and OZEM stand out.